Scholar Rock Holdings: Between Approval Hopes and Billion-Dollar Niche

Scholar Rock is the first company to achieve clinical Phase-3 success with a highly selective myostatin inhibitor (Apitegromab), potentially revolutionizing the treatment of degenerative muscle diseases.   With the expected US approval in 2026 and simultaneous market entry in Europe (starting in Germany), the company is poised to transition from a pure research operation to a commercial pharmaceutical player.   By developing SRK-439, the company is positioning itself in a lucrative niche of the obesity market, aimed at preserving muscle...